KX-01 demonstrates at least two MOAs relevant to the control of cancer and hyper-proliferative disorders: Src tyrosine kinase inhibition (non-ATP competitive) and tubulin polymerization inhibition. Src plays a demonstrated role in regulating multiple aspects of tumor development, growth, and metastases, and its inhibition limits such tumor activity. Interfering with tubulin polymerization activity is a clinically validated mechanism for treating cancer. For both targets KX- 01 binds at a novel binding site. Taken together, these two MOAs provide for a potent means of treating cancer and other hyper-proliferative disorders.

KX-01 oral has been evaluated in several early dose finding studies against both solid and liquid tumors. Initial clinical results indicate activity against both solid and liquid tumors in patients. We are planning further probing studies to focus our evaluation on those indications where activity was observed.

Clinical Trial Pipeline

KX01 (Oral) Territory Indication Sponsor/Partner Pre-Clinical Phase I Phase II Phase III
KX01-01-07 United States Solid Tumor Athenex
Completed
KX01-02-09 United States Prostate Athenex
Completed
KX01-03-11 United States Acute Myelogenous Leukemia Athenex
Completed
HM-KX1-101 South Korea Solid Tumor Hanmi
Enrollment Completed
KX01-CA-001 Taiwan Ovarian Athenex
Planned Q2/2018
KX01-CA-002 Taiwan Liquid Tumor Athenex
Planned Q2/2018